December 10 2020
Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.
December 9 2020
Investigators explained the potential for durable antitumor efficacy in patients with human epidermal growth factor receptor 2 (HER2)-expressing or -driven tumors who have exhausted other treatment options.
December 8 2020
A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.